Enveric Biosciences, Inc. ENVB
1.50
(0.05)
(3.23%)
as of 25 Sep
- Market cap
- $6.9M
- P/E
- 0.0×
Follow ENVB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
4.15 | 5.09 | 10.66 | 9.63 | |
Current Ratio |
4.60 | 5.38 | 11.67 | 10.21 | |
Net Debt/EBITDA |
2.05 | 2.17 | 3.08 | 2.77 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.61 | 0.44 | 1.38 | 0.81 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(6.63) | (5.33) | (1.49) | (0.61) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(6.63) | (5.33) | (1.49) | (0.61) | |
Cash per Share |
12.00 | 13.98 | 3.25 | 2.08 | |
Shareholders Equity per Share |
11.04 | 12.48 | 3.35 | 2.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
11.04 | 12.48 | 3.35 | 2.03 | |
Free Cash Flow |
(2.07) | (1.78) | (2.26) | (2.44) | |
Working Capital |
3.26 | 4.02 | 4.91 | 7.93 | |
Net Current Asset Value |
3.26 | 4.02 | 4.91 | 7.93 | |
EV/EBIT |
— | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
0.63 | 0.55 | 0.47 | 0.86 | |
Average Assets |
4.58 | 4.09 | 5.31 | 6.25 | |
Average Common Equity |
3.70 | 2.89 | 4.49 | 5.13 |
Columns are period end dates